Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral,… Read more
Market Cap & Net Worth: Pliant Therapeutics Inc (PLRX)
Pliant Therapeutics Inc (NASDAQ:PLRX) has a market capitalization of $81.73 Million ($81.73 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19846 globally and #7265 in its home market, demonstrating a 0.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pliant Therapeutics Inc's stock price $1.33 by its total outstanding shares 61449385 (61.45 Million).
Pliant Therapeutics Inc Market Cap History: 2020 to 2026
Pliant Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $1.40 Billion to $81.73 Million (-38.07% CAGR).
Index Memberships
Pliant Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #545 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1813 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.00% | #239 of 263 |
Weight: Pliant Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pliant Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pliant Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
704.33x
Pliant Therapeutics Inc's market cap is 704.33 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.40 Billion | $41.82 Million | -$39.74 Million | 33.39x | N/A |
| 2021 | $829.57 Million | $7.57 Million | -$17.91 Million | 109.56x | N/A |
| 2022 | $1.19 Billion | $9.69 Million | -$123.32 Million | 122.64x | N/A |
| 2023 | $1.11 Billion | $1.58 Million | -$161.34 Million | 704.33x | N/A |
Competitor Companies of PLRX by Market Capitalization
Companies near Pliant Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Pliant Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pliant Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Pliant Therapeutics Inc's market cap moved from $1.40 Billion to $ 81.73 Million, with a yearly change of -38.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $81.73 Million | +9.02% |
| 2025 | $74.97 Million | -90.74% |
| 2024 | $809.29 Million | -27.28% |
| 2023 | $1.11 Billion | -6.31% |
| 2022 | $1.19 Billion | +43.19% |
| 2021 | $829.57 Million | -40.58% |
| 2020 | $1.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pliant Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $81.73 Million USD |
| MoneyControl | $81.73 Million USD |
| MarketWatch | $81.73 Million USD |
| marketcap.company | $81.73 Million USD |
| Reuters | $81.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.